Jump Financial’s Arcturus Therapeutics ARCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$409K Sell
29,879
-108,330
-78% -$1.13M ﹤0.01% 1798
2026
Q2
$929K Buy
138,209
+69,916
+102% +$551K 0.01% 1225
2026
Q1
$527K Buy
+68,293
New +$498K 0.01% 1212
2025
Q1
– Sell
-58,308
Closed -$989K – 1576
2024
Q4
$989K Sell
58,308
-2,458
-4% -$46.3K 0.02% 757
2024
Q3
$1.41M Buy
60,766
+44,918
+283% +$961K 0.03% 651
2024
Q2
$386K Buy
+15,848
New +$481K 0.01% 1252
2023
Q3
– Sell
-7,992
Closed -$229K – 1826
2023
Q2
$229K Sell
7,992
-33,749
-81% -$919K 0.01% 1456
2023
Q1
$1M Buy
41,741
+21,263
+104% +$381K 0.04% 597
2022
Q4
$347K Buy
+20,478
New +$357K 0.02% 955
2022
Q3
– Sell
-24,954
Closed -$393K – 1560
2022
Q2
$393K Buy
+24,954
New +$490K 0.02% 949
2022
Q1
– Sell
-30,443
Closed -$1.13M – 1528
2021
Q4
$1.13M Buy
+30,443
New +$1.24M 0.07% 355
2021
Q2
– Sell
-35,400
Closed -$1.46M – 1069
2021
Q1
$1.46M Buy
+35,400
New +$2.11M 0.14% 166

Other funds holding ARCT

Jump Financial's ARCT Position: Q3 2026 in Review

Jump Financial reduced its Arcturus Therapeutics (ARCT) stake by 78% in Q3 2026, selling an estimated $1.13M and leaving 29,879 shares worth $409K. The position accounts for ﹤0.01% of the portfolio, ranked #1798.

Jump Financial first reported a position in ARCT in Q1 2021 and has held it in 12 quarters since. The position peaked at $1.46M in Q1 2021. 155 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

  • Jump Financial held 29,879 shares of Arcturus Therapeutics worth $409K as of Q3 2026.
  • Jump Financial sold 108,330 Arcturus Therapeutics shares in Q3 2026, an estimated $1.13M.
  • Arcturus Therapeutics made up ﹤0.01% of Jump Financial's portfolio in Q3 2026, its #1798 holding.
  • Jump Financial first reported a position in Arcturus Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • Jump Financial's Arcturus Therapeutics position peaked at $1.46M in Q1 2021.
  • 155 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Jump Financial's 13F filing for Q3 2026, filed 13 Nov 2026.